Terns Pharmaceuticals, Inc.

Industry

  • Pharmaceuticals
    • Vaccines
    • Specialty Pharmaceuticals
  • Biotechnology
See more in Biomedtracker

Latest on Terns Pharmaceuticals, Inc.

Scrip

Ascletis Becomes Another Contender For ‘Best-In-Class’ Oral GLP-1

 
• By Andrew McConaghie

Ascletis Pharma only joined the obesity field last September but has just presented early data for what could be a best-in-class oral GLP-1 agonist. Data from the Phase Ib MAD study show the Hong Kong

Pink Sheet

After Ocaliva: US FDA Sees Breakthrough Potential In New Approaches To Liver Disease

 
• By Bridget Silverman

A cluster of recent breakthrough therapy designation awards in liver disease highlight advances in the field ahead of the US Food and Drug Administration’s difficult, and now delayed, decision on the

Scrip

Finance Watch: Follow-Ons Bring In Big Post-Data Cash For Nuvalent And Others

 
• By Mandy Jackson

Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from

Scrip

Terns’ Early Data May Position It Well In GLP-1 Obesity Race

 
• By Joseph Haas

The obesity space may have another serious entry as Terns Pharmaceuticals, Inc. unveiled Phase I data for its oral, daily GLP-1 agonist TERN-601 on 9 September that indicate competitive weight-loss